Clinical Trial Update: HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating hydrochlorothiazide to protect autosomal dominant polycystic kidney disease patients and improve quality of life is currently …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• HYDROCHLOROTHIAZIDE (hydrochlorothiazide)

Snippet

Sponsor: University Medical Center Groningen | Conditions: ADPKD | Phase 3 | Status: RECRUITING